期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 65, 期 3, 页码 379-382出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkp492
关键词
liver; tenofovir; drug resistance; vaccine escape mutants
资金
- Fundacion Investigacion y Educacion en SIDA (IES)
- European NEAT
- Red de Investigacion en SIDA [RD06/006]
Until the advent of tenofovir, many HIV/hepatitis B virus (HBV) co-infected patients had been treated with lamivudine as the only agent active against HBV. Selection of lamivudine-resistant HBV strains occurred in many of these patients, complicating clinical prognosis and rescue therapy. These individuals might also transmit HBV-resistant strains. Moreover, a subset of these lamivudine-resistant HBV isolates may behave as vaccine escape mutants, complicating diagnostic accuracy (e.g. producing 'occult' hepatitis B) and reducing the efficacy of preventive measures (causing infection in vaccinated persons). Nowadays, periodic monitoring of HBV viral load in co-infected patients should be mandatory. It may allow the early recognition of HBV viraemic individuals who may benefit from either initiating or switching antiviral therapy. In any situation, the use of anti-HBV therapies more potent than lamivudine alone is warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据